Overview

Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes

Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the time-course of the antiproteinuric effect of renin inhibition with Aliskiren in patients with Type 2 diabetes suffering from incipient and/or established nephropathy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Novartis